These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3678067)

  • 21. Adverse event detection in drug development: recommendations and obligations beyond phase 3.
    Berlin JA; Glasser SC; Ellenberg SS
    Am J Public Health; 2008 Aug; 98(8):1366-71. PubMed ID: 18556607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What you should know about FDA-USP Drug Product Problem Reporting Program.
    McGinnis DM
    Pharm Times; 1986 Apr; 52(4):101-4, 109. PubMed ID: 10276472
    [No Abstract]   [Full Text] [Related]  

  • 23. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Problems of the number of cases in drug surveillance].
    Auriche M
    Rev Med Interne; 1986 Nov; Spec No():45-51. PubMed ID: 3809780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating and monitoring the safety and efficacy of drug therapy and surgery.
    Stolley PD; Strom BL
    J Chronic Dis; 1986; 39(12):1145-55. PubMed ID: 3539972
    [No Abstract]   [Full Text] [Related]  

  • 26. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug surveillance. Establishment of a benefit/risk ratio in current practice].
    Demarez JP; Couzinier JP; Begaud B
    Therapie; 1985; 40(5):333-5. PubMed ID: 4095691
    [No Abstract]   [Full Text] [Related]  

  • 28. A clinical pharmacy-oriented drug surveillance network: I. Program description.
    Grasela TH; Schentag JJ
    Drug Intell Clin Pharm; 1987 Nov; 21(11):902-8. PubMed ID: 3678065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability of adverse drug reaction assessment in psychiatric inpatients.
    Grohmann R; Dirschedl P; Scherer J; Schmidt LG; Wunderlich O
    Drug Inf J; 1986; 20(3):357-61. PubMed ID: 10278515
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
    Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW
    Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing studies of drug efficacy: how?
    Strom BL; Miettinen OS; Melmon KL
    Am J Med; 1984 Oct; 77(4):703-8. PubMed ID: 6486146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 35. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Moro PL; Cano M; Jankosky C
    Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse drug reaction processing in the United States and its dependence on physician reporting: zomepirac (Zomax) as a case in point.
    Corre KA; Spielberg TE
    Ann Emerg Med; 1988 Feb; 17(2):145-9. PubMed ID: 3257365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing follow-up: physicians have key role.
    Goldsmith MF
    JAMA; 1985 Oct; 254(16):2217. PubMed ID: 4046146
    [No Abstract]   [Full Text] [Related]  

  • 39. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
    Kraft WK; Waldman SA
    Drug Saf; 2001; 24(9):637-43. PubMed ID: 11522118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A potential use of the National Death Index for postmarketing drug surveillance.
    Edlavitch SA; Feinleib M; Anello C
    JAMA; 1985 Mar; 253(9):1292-5. PubMed ID: 3968855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.